How Vascepa Lowers Cardiovascular Risk
Vascepa (icosapent ethyl) reduces major cardiovascular events in high-risk patients. In the REDUCE-IT trial, it cut the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina by 25% compared to placebo in adults with elevated triglycerides (135-499 mg/dL) on statin therapy.[1][2] The FDA approved it for this use in December 2019 based on these results.
Who Qualifies for These Benefits
Benefits apply to patients with established cardiovascular disease or diabetes plus other risk factors (like age ≥50 with one extra factor such as hypertension or smoking). It targets those already on statins but with persistent high triglycerides, not as a first-line lipid treatment.[1]
Effects on Triglycerides and Other Lipids
Vascepa lowers triglycerides by 18-45% at doses of 2g twice daily, without raising LDL-C levels—a key edge over mixed omega-3 products.[2] It also reduces apolipoprotein C-III, remnant cholesterol, and oxidized LDL, which contribute to plaque buildup.[3]
How It Differs from Fish Oil or Lovaza
Pure EPA in Vascepa avoids DHA-related LDL increases seen in prescription fish oil (Lovaza). REDUCE-IT showed superior CV risk reduction versus mineral oil placebo; real-world data like EVAPORATE confirmed plaque regression.[2][4] Over-the-counter fish oil lacks this evidence and potency.
Common Side Effects Patients Report
Most tolerate it well, but risks include atrial fibrillation (up to 5% higher), bleeding (3% higher), and muscle pain. It's not for triglyceride levels ≥500 mg/dL without CV risk—use fibrates there instead.[1]
Cost and Access Considerations
Pure Vascepa costs $300-400/month without insurance; generics launched in 2020 after patent challenges. Patient assistance programs cover eligible uninsured.[5] For patent details, see DrugPatentWatch.com.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s024lbl.pdf
[2] REDUCE-IT Trial (NEJM 2019): https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[3] Amarin Pharma data: https://www.vascepa.com
[4] EVAPORATE Trial: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048611
[5] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/VASCEPA